EIKO Lifesciences Limited has announced an Extra-Ordinary General Meeting (EGM) scheduled for January 7, 2026, at 3:00 PM IST through video conferencing. The meeting will seek shareholder approval for a comprehensive fundraising initiative worth ₹21.86 crores through preferential allotment of securities.

Fundraising Structure and Allocation

The company's Board of Directors, in their meeting held on December 11, 2025, approved a two-pronged fundraising approach comprising warrants and equity shares:

The warrants will be convertible into equity shares within 18 months from the allotment date, with each warrant carrying a face value of ₹10.00 and a premium of ₹45.00.

Strategic Investment Objectives

The primary purpose of the fundraising is strategic acquisition and expansion. The company intends to utilize ₹14.44 crores from the warrant proceeds for acquiring the remaining requisite stake in SSM Formulations Private Limited. Upon completion, EIKO Lifesciences will hold a cumulative 51% equity stake in SSM Formulations, making it a subsidiary.

The strategic acquisition will enable the company to expand its product portfolio, enter new markets, and leverage SSM Formulations' manufacturing capabilities for long-term stakeholder value creation.

Allottee Details and Participation

The preferential issue includes participation from both promoter and non-promoter categories:

Warrant Allottees:

Equity Share Allottees:

Pricing and Regulatory Compliance

The issue price of ₹55.00 per security has been determined based on SEBI ICDR Regulations pricing guidelines. The relevant date for floor price determination is December 8, 2025, being 30 days prior to the EGM date. The pricing represents the higher of:

• 90 trading days VWAP: ₹54.98 per equity share
• 10 trading days VWAP: ₹51.26 per equity share

The company has obtained necessary valuation reports and chartered accountant certificates as required under regulatory frameworks.

Terms and Conditions

Key terms for the warrant issue include:

• Payment Structure: 25% of warrant price payable at allotment, balance 75% upon exercise
• Exercise Period: 18 months from allotment date
• Lock-in Period: As prescribed under SEBI ICDR Regulations
• Conversion: Each warrant convertible into one equity share of ₹10.00 face value
• Lapse Provision: Unexercised warrants will lapse after 18 months, with amounts forfeited

The equity shares and converted shares from warrants will rank pari-passu with existing equity shares in all respects, including dividend and voting rights.

Meeting and Voting Details

The EGM will be conducted through video conferencing, with the cut-off date for voting eligibility set as January 2, 2026. Remote e-voting will commence on January 4, 2026, at 9:00 AM and conclude on January 6, 2026, at 5:00 PM. The company has appointed Shravan Gupta, Practicing Company Secretary, as the scrutinizer for the voting process.

Shareholders can access the complete notice and related documents on the company's website at www.eikolifesciences.com and the registrar's portal at https://ivote.bigshareonline.com/landing .

EIKO Lifesciences Limited has announced a definitive agreement to acquire a 51% equity stake in SSM Formulations Private Limited, a WHO-GMP accredited pharmaceutical formulations company based in Hinganghat, Wardha. This strategic acquisition, valued at ₹18.00 crores, marks a significant milestone for EIKO Lifesciences, expanding its capabilities from a specialty chemicals and API supplier to a fully integrated pharmaceutical player with a global footprint in Finished Dosage Forms.

Strategic Acquisition Details

The board of directors approved the acquisition during their meeting held on December 11, 2025. The transaction will be executed in a phased manner aligned with EIKO Lifesciences' strategic fundraising through warrants.

SSM Formulations Business Profile

SSM Formulations operates a WHO-GMP accredited facility with expansion-ready infrastructure including an additional 5,000 sq. ft. on the first floor. The company has demonstrated strong business performance with substantial turnover across recent financial years.

Strategic Capabilities and Market Position

SSM brings high-barrier capabilities including Narcotics License with Tramadol registrations in Ghana and Nigeria, along with registrations in Uzbekistan, Yemen, Nigeria, Ghana, and Cameroon. The company holds 199 Product Manufacturing Permissions, 157 Testing Permissions, and 74 COPPs with WHO-GMP certification.

Fundraising Initiative

The board approved raising funds through the issuance of up to 33,00,000 warrants and 6,75,000 equity shares to support the acquisition and growth plans.

Management Commentary and Strategic Vision

Mr. Laxmikant Ramprasad Kabra, Director of EIKO Lifesciences Limited, emphasized the transformative nature of the acquisition, stating it represents a multiplier effect for the company. He highlighted SSM's extensive manufacturing base and foothold in over five international markets, with plans to transform SSM into a global export hub by combining EIKO Lifesciences' financial strength with SSM's operational excellence.

The acquisition enables vertical integration by manufacturing finished formulations using EIKO Lifesciences' own API supply chain to capture full value-chain margins. The strategic move aims to create a diversified revenue mix across APIs, specialty chemicals, government tenders, and branded exports while targeting rapid scale-up to 90% capacity utilization.

The board has scheduled an Extraordinary General Meeting for January 7, 2026, at 3:00 PM through video conferencing to seek necessary shareholder approvals for the transaction.